Literature DB >> 3039178

A mouse model for poliovirus neurovirulence identifies mutations that attenuate the virus for humans.

N La Monica, J W Almond, V R Racaniello.   

Abstract

A mutation in the genome of poliovirus type 3 that is known to reduce neurovirulence in humans similarly reduces neurovirulence in mice when incorporated into a mouse-adapted-human poliovirus recombinant. Viral recombinants with a uracil at nucleotide position 472 in the 5'-noncoding regions of their genomes are unable to replicate in the mouse brain. Viral recombinants with a cytosine at this position are neurovirulent in mice. Neurovirulence of poliovirus in mice may therefore prove to be a useful indicator of the genetic stability of new attenuating mutations created by site-directed mutagenesis.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3039178      PMCID： PMC255821          DOI： 10.1128/JVI.61.9.2917-2920.1987

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  14 in total

1.  Three-dimensional structure of poliovirus at 2.9 A resolution.

Authors:  J M Hogle; M Chow; D J Filman
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

Review 2.  New poliovirus vaccines: a molecular approach.

Authors:  J W Almond; G Stanway; A J Cann; G D Westrop; D M Evans; M Ferguson; P D Minor; M Spitz; G C Schild
Journal:  Vaccine       Date:  1984-09       Impact factor: 3.641

3.  Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome.

Authors:  V R Racaniello; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

4.  Cloned poliovirus complementary DNA is infectious in mammalian cells.

Authors:  V R Racaniello; D Baltimore
Journal:  Science       Date:  1981-11-20       Impact factor: 47.728

5.  Modification of calmodulin function by enzymatic carboxylic methylation.

Authors:  C Gagnon; S Kelly; V Manganiello; M Vaughan; C Odya; W Strittmatter; A Hoffman; F Hirata
Journal:  Nature       Date:  1981-06-11       Impact factor: 49.962

6.  Characterization of strains of type 3 poliovirus by oligonucleotide mapping.

Authors:  P D Minor
Journal:  J Gen Virol       Date:  1982-04       Impact factor: 3.891

7.  Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome.

Authors:  D M Evans; G Dunn; P D Minor; G C Schild; A J Cann; G Stanway; J W Almond; K Currey; J V Maizel
Journal:  Nature       Date:  1985 Apr 11-17       Impact factor: 49.962

8.  Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing.

Authors:  N La Monica; C Meriam; V R Racaniello
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

9.  Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3.

Authors:  D M Evans; P D Minor; G S Schild; J W Almond
Journal:  Nature       Date:  1983 Aug 4-10       Impact factor: 49.962

10.  Multiple genetic changes can occur in the oral poliovaccines upon replication in humans.

Authors:  O M Kew; B K Nottay; M H Hatch; J H Nakano; J F Obijeski
Journal:  J Gen Virol       Date:  1981-10       Impact factor: 3.891
View more
  35 in total

1.  Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease.

Authors:  Matthew Frieman; Boyd Yount; Sudhakar Agnihothram; Carly Page; Eric Donaldson; Anjeanette Roberts; Leatrice Vogel; Becky Woodruff; Diana Scorpio; Kanta Subbarao; Ralph S Baric
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Determination of the structure of a decay accelerating factor-binding clinical isolate of echovirus 11 allows mapping of mutants with altered receptor requirements for infection.

Authors:  Amanda D Stuart; Thomas A McKee; Pamela A Williams; Chris Harley; Shuo Shen; David I Stuart; T David K Brown; Susan M Lea
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

3.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

4.  The 5' noncoding sequences from a less virulent Theiler's virus dramatically attenuate GDVII neurovirulence.

Authors:  H L Lipton; M Calenoff; P Bandyopadhyay; S D Miller; M C Dal Canto; S Gerety; K Jensen
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Chimeric picornavirus polyproteins demonstrate a common 3C proteinase substrate specificity.

Authors:  P G Dewalt; M A Lawson; R J Colonno; B L Semler
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

6.  Construction of less neurovirulent polioviruses by introducing deletions into the 5' noncoding sequence of the genome.

Authors:  N Iizuka; M Kohara; K Hagino-Yamagishi; S Abe; T Komatsu; K Tago; M Arita; A Nomoto
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

7.  The reovirus M1 gene, encoding a viral core protein, is associated with the myocarditic phenotype of a reovirus variant.

Authors:  B Sherry; B N Fields
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  Substitutions in the capsids of poliovirus mutants selected in human neuroblastoma cells confer on the Mahoney type 1 strain a phenotype neurovirulent in mice.

Authors:  T Couderc; N Guédo; V Calvez; I Pelletier; J Hogle; F Colbère-Garapin; B Blondel
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Transgenic mice susceptible to poliovirus.

Authors:  S Koike; C Taya; T Kurata; S Abe; I Ise; H Yonekawa; A Nomoto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

10.  Identification of two determinants that attenuate vaccine-related type 2 poliovirus.

Authors:  R B Ren; E G Moss; V R Racaniello
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.